Amplifica Appoints Hans Hofland, Ph.D., as Chief Development Officer and William Humphries to Board of Directors
核心洞察
Amplifica Holdings Group, a clinical-stage biopharmaceutical company, has appointed Hans Hofland (搜索), Ph.D., as Chief Development Officer and William Humphries (搜索) to its board of directors.
Dr. Hofland brings more than 30 years of drug discovery and development experience, having contributed to 13 investigational new drug applications and advanced 10 product candidates into clinical development.
The appointments strengthen Amplifica's dermatology expertise as it advances its pipeline of product candidates designed to reactivate dormant hair follicles and promote new hair growth.
Amplifica Holdings Group, Inc. (搜索), a privately held, clinical-stage biopharmaceutical company developing novel therapies for hair growth, announced the appointment of Hans Hofland (搜索), Ph.D., as Chief Development Officer and William Humphries (搜索) to its board of directors. The appointments, announced from San Diego, strengthen the company's leadership with extensive experience spanning dermatology research and development, clinical translation, commercialization, and corporate strategy as Amplifica advances its pipeline of product candidates designed to reactivate dormant hair follicles and promote new hair growth.
"Hans and Bill bring distinct yet mutually reinforcing expertise at a pivotal stage for Amplifica," said Frank Fazio, President and Chief Executive Officer of Amplifica. "Hans has a strong record of advancing dermatology research programs into the clinic across multiple therapeutic modalities, while Bill has led and advised companies across the dermatology and broader healthcare sectors. Their perspectives will be invaluable as we execute our development strategy and build a leading company in hair-growth innovation."
Leadership Experience in Dermatology Drug Development
Dr. Hofland is a biopharmaceutical executive with more than 30 years of experience in drug discovery and development, translational research, and clinical development. He has advanced dermatology therapeutics from early discovery through first-in-human studies across small molecules, nucleic acid-based therapies, and biologics. His leadership experience includes roles at Connetics, Stiefel Laboratories, GlaxoSmithKline, and Dermira, as well as co-founding Evommune and leading discovery and preclinical development at Turn Biotechnologies and Soleno Therapeutics.
Dr. Hofland has contributed to 13 investigational new drug applications and helped advance 10 product candidates into clinical development and commercialization. He earned a Ph.D. in Pharmaceutical Sciences from Leiden University and completed postdoctoral training at the University of Pittsburgh.
Mr. Humphries is an experienced healthcare executive and board director with deep expertise in dermatology, pharmaceuticals, and contract development and manufacturing. He currently serves as Chief Executive Officer and a director of MedPharm and has served on the board of Aclaris Therapeutics since 2016. Previously, he led Alcami, Isosceles Pharmaceuticals, Ortho Dermatologics, and Merz's North American business, and held senior leadership roles at Stiefel Laboratories and Allergan. Mr. Humphries also serves as a director of Cutera and has held board positions at several public and private healthcare companies. He earned a B.A. from Bucknell University and an M.B.A. from Pepperdine University.
A Nature-Inspired Approach to Hair Regrowth
Amplifica is a clinical-stage biopharmaceutical company focused on developing novel treatments for androgenetic alopecia (搜索) (hair loss), a condition estimated to affect more than 50 million men and more than 30 million women in the United States alone. The company is taking a nature-inspired scientific approach using molecular mechanisms designed to regrow natural hair.
Amplifica has identified and isolated unique signaling molecules that stimulate hair follicles to regrow hair and is advancing product development programs and clinical trials to evaluate the safety and efficacy of its core technology, subject to applicable regulatory approvals.